Human PAI-1 (stable vitronectin reduced bi*ding mutant) *di

Store at -80C. Stable for 3 years from delivery. For long term use, divide into working aliquots and freeze at -80C. Avoid repeated freeze-thaw cycles.

Plasminogen Activator Inhibitor 1 (PAI-1), also known as Serpin peptidase inhibitor, clade E (SERPINE1), is a member of the serine protease inhibitor (serpin) superfamily. It is the principal inhibitor of Tissue Plasminogen Activator (tPA) and Urokinase (uPA), the activators of Plasminogen and hence fibrinolysis. PAI-1 is mainly produced by the endothelium, but is also secreted by other tissue types, such as adipose tissue. Defects in the PAI-1 gene are the cause of plasminogen activator inhibitor-1 deficiency (PAI-1 deficiency), and high concentrations of the protein are associated with thrombophilia. The Recombinant Human Serpin E1/PAI-1 Stable Vitronectin Reduced-Binding Point Mutant is produced by the mutagenesis of the Q123K residue on the Human Serpin E1/PAI-1 stable mutant background (K154T, Q319L, M354I and N150H) resulting in a PAI-1 with greatly extended half life and reduced binding to the vitronectin ligand.

< 0.1 ng/ug of protein.